These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 3986938)

  • 1. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
    Nichols L; Maki DG
    Chemioterapia; 1985 Feb; 4(1):102-9. PubMed ID: 3986938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
    Lerner SA; Quinn JP
    Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
    Pagani L; Scarabelli M; Cereda PM; Debiaggi M
    Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.
    Michalsen H; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():92-7. PubMed ID: 6947408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.
    Bliziotis IA; Samonis G; Vardakas KZ; Chrysanthopoulou S; Falagas ME
    Clin Infect Dis; 2005 Jul; 41(2):149-58. PubMed ID: 15983909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Choice of a rapidly bactericidal beta-lactamin-aminoglycoside combination in the treatment of Pseudomonas aeruginosa infections at a child intensive care unit].
    Lambert-Zechovsky N; Bingen E; Guihaire E; Mancy C; Mercier JC; Beaufils F
    Pathol Biol (Paris); 1986 Sep; 34(7):855-8. PubMed ID: 3537930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
    Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
    Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycosides versus beta-lactams in gram-negative pneumonia.
    Collins T; Gerding DN
    Semin Respir Infect; 1991 Sep; 6(3):136-46. PubMed ID: 1754734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycosides are useful for severe respiratory tract infections.
    Craig WA; Andes D
    Semin Respir Infect; 1997 Dec; 12(4):271-7. PubMed ID: 9436954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
    Lode H
    Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
    Wu YL; Scott EM; Po AL; Tariq VN
    APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of aztreonam, other beta-lactam antibiotics and aminoglycosides against Pseudomonas aeruginosa.
    Venditti M; Brandimarte C; Santini C; Valente B; Martino P; Serra P
    Chemioterapia; 1984 Aug; 3(4):258-61. PubMed ID: 6442625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.